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Case description 
A 38-year old male patient with pharmacoresistant bilateral temporal-lobe epilepsy 
was referred to our department for adjustment of antiepileptic-drug dosage with continuous 
Video-EEG monitoring.  
In 2013, bilateral deep brain electrodes were implanted for chronic stimulation in both 
anterior thalamic nuclei. After implantation, the patient remained seizure free of generalized 
tonic-clonic seizures, but continued to experience daily complex-partial seizures typically 
presenting with initial dizziness, shortness of breath and a short period of unresponsiveness. 
Before admission, he was treated with levetiracetam (1g twice a day), lamotrigine (500mg 
twice a day) and oxcarbazepine (600mg twice a day). Due to insufficient seizure control and 
likely levetiracetam-associated aggressive behavior the following modifications were applied: 
At admission (day 1) levetiracetam dosage was reduced to the half (and completely stopped 
on day 3), while valproid acid was started at a low dose (300mg twice a day). Accidentally, 
on day 2 the oxcarbazepine dosage was doubled in the evening (from 600mg to 1200mg). The 
next day (day 3) the patient again received the double oxcarbazepine dose in the morning and 
few hours later he presented with acute vertigo, nausea and vomiting. Continuous EEG-
monitoring showed steep surface-negative excursions followed by shallow return to baseline 
(frequency = 2-3/sec) that were most prominent in frontal derivations after eyes opening 
(Figure 1A, arrows). This pattern was interpreted as rhythmic eye movements with slow 
upward phase and fast downward phase, i.e., downbeat-nystagmus (DBN). On clinical 
neurological examination DBN was confirmed, while no other focal neurological deficits 
were found. Emergency brain CT was reportedly normal, excluding structural causes of acute 
DBN. Oxcarbazepine serum levels were supra-therapeutic (147.4µmol/l, therapeutic range = 
11.8-138µmol/l; baseline serum level at admission: 72.8µmol/l), while serum levels of the 
other antiepileptic drugs either remained in the established therapeutic range (lamotrigine: 
38.2µmol/l, therapeutic range=9.8-58.6) or did not reach therapeutic levels yet (valproid acid: 
	 3 
145µmol/l, therapeutic range=350-700). The increased DBN therefore most likely reflected 
acute oxcarbazepine-induced cerebellar dysfunction, resulting in impaired vertical gaze 
holding. Potentially, the simultaneous addition of valproid acid further increased 
oxcarbazepine serum levels as a result of its known enzyme inhibiting effect. The patient was 
transferred to intermediate care unit for monitoring and oxcarbazepine dosage was lowered 
again. Serum oxcarbazepine levels returned to the therapeutic range (41.3µmol/l) on day 5 
and the patient’s acute cerebellar signs and symptoms including DBN resolved completely. 
The reversibility of DBN was also demonstrated on re-established EEG-monitoring on day 5 
(Figure 1B).  
Posterior cerebellar lesions involving median/paramedian structures and especially the 
flocculus and the paraflocculus have been linked to DBN [1], typically demonstrating 
cerebellar atrophy in chronic cases. In patients with acute DBN, metabolic-toxic and 
structural causes such as lesions of the craniocervical junction including Arnold-Chiari 
malformation may cause cerebellar dysfunction. Neurotoxic effects of antiepileptic drugs 
resulting in DBN were frequently observed in patients with phenytoin [2] or carbamazepine 
overdosage [2, 3] and was shown to be reversible after adjustment of dose and subsequent 
reduction of drug blood levels. In the previous literature we identified however only a single 
patient with acute DBN caused by oxcarbazepine intoxication [4]. In contrast to 
carbamazepine, oxcarbazepine is not metabolized to an active toxic epoxide metabolite and 
intoxication symptoms are usually mild, which might explain why DBN in oxcarbazepine 
intoxication has rarely been reported.  
Known as a sign of cerebellar loss of function [1], new-onset DBN on EEG and on 
clinical examination should prompt checking for structural lesions and drug toxicity in 
patients under antiepileptic drug-treatment. Prognosis of acute drug-induced DBN is usually 
excellent after adjustment of antiepileptic drug dosage and reduction of serum levels. This is 
in contrast to chronic DBN, which may be found in antiepileptic drug-induced cerebellar 
	 4 
degeneration (e.g., due to long-term phenytoin-intake) [5] and is usually persistent after 
cessation of the causing agent.  
 
Figure 1:  
EEG-recording in longitudinal bipolar montage (10/20 system). Panel A: At the time of 
oxcarbazepine intoxication (day 3), steep surface-negative excursions (arrows) are followed 
by more slow return to baseline. Considering eyeball polarity (positive to negative from 
ventral to caudal) this indicates slow upward eye-drift followed by fast downward saccades, 
consistent with DBN. Note that eye lid movements will contribute to these EEG changes as 
well [6]. Panel B: 48 hours later DBN had resolved, consistent with the return of 
oxcarbazepine blood levels to the therapeutic range.  
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